SOUTH SAN FRANCISCO, Calif. - Lyell Immunopharma, Inc. (NASDAQ:LYEL) announced it will present data from its Phase 1/2 clinical trial of rondecabtagene autoleucel in patients with relapsed or refractory large B-cell lymphoma at the European Hematology Association 2026 Congress in Stockholm, Sweden, June 11-14, 2026.
The company will feature two poster presentations on Friday, June 12 at 12:45 pm EDT. The first poster will cover an updated safety analysis of ronde-cel, a dual-targeting CD19/CD20 CAR T-cell product candidate. The second poster will examine translational insights related to durable responses and cytotoxic T cells with memory potential in infusion products.The presentations come as Lyell’s stock trades at $13.05, down 25% over the past week, giving the company a market cap of $300 million. According to InvestingPro analysis, the stock appears undervalued at current levels. The company maintains a strong current ratio of 7.23, though InvestingPro Tips highlight it is quickly burning through cash—one of 14 additional insights available to subscribers.
Ronde-cel is currently being evaluated for the treatment of relapsed or refractory large B-cell lymphoma across two pivotal clinical trials, according to the press release statement. The ongoing single-arm PiNACLE trial in the third-line or later setting is expected to report updated data in the second half of 2026 and pivotal data by mid-2027. A Biologics License Application submission is planned for 2027.
In the second-line setting, the Phase 3 randomized PiNACLE-H2H trial is evaluating ronde-cel against investigator’s choice of axicabtagene ciloleucel or lisocabtagene maraleucel.
The posters will be available on the company’s website after the presentations.
Lyell Immunopharma develops CAR T-cell therapies for patients with hematologic malignancies and solid tumors. The company’s LyFE facility is expected to have the capacity to manufacture more than 1,200 CAR T-cell doses per year.
In other recent news, Lyell Immunopharma has been the focus of several analyst evaluations and corporate developments. H.C. Wainwright reiterated its Buy rating on the company, maintaining a price target of $45.00. The firm highlighted the commencement of patient dosing in the Phase 3 PiNACLE-H2H trial, which involves the company’s ronde-cel therapy for large B cell lymphoma. In another update, Baird initiated coverage on Lyell Immunopharma with an Outperform rating and a price target of $49.00, emphasizing the potential of its pipeline, particularly the ongoing pivotal studies for ronde-cel. Meanwhile, BofA Securities maintained an Underperform rating with a $12.00 price target following Johnson & Johnson’s decision to discontinue a competing therapy, removing a rival from the treatment landscape. Citizens also reiterated a Market Outperform rating for Lyell Immunopharma, setting a price target of $34.00 based on a revenue and earnings multiple analysis. These developments come as Lyell Immunopharma recently reported its fourth-quarter earnings for 2025 and provided updates on its corporate progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for LYEL plus thousands of other stocks and find your next hidden gem with massive upside.